A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Research highlights media misrepresentation of COVID-19 drug efficacy. ... For the study, the researchers conducted an analysis of 479 reports of hydroxychloroquine, ...

However, the efficacy estimates of the COVID-19 vaccines from the trials mentioned above were much higher than the FDA and WHO threshold. In all the different trials, different factors have been ...

A final analysis confirmed that Pfizer’s investigational oral antiviral, Paxlovid, reduced the risk for severe COVID-19 outcomes by almost 90% when given within days of symptom onset, as first ...

Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its ...

The updated trial analysis (ClinicalTrials.gov Identifier: NCT04575597) included 1433 adults with mild to moderate COVID-19 with symptom onset within 5 days of randomization.

Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously ...

Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle–encapsulated mRNA ...

AstraZeneca said its latest figure on the vaccine’s efficacy was based on an analysis of 190 cases of symptomatic Covid-19 in the trial, 49 more cases than the company had analyzed earlier ...

A preliminary analysis showed that CureVac’s ... Both the World Health Organization and the Food and Drug Administration set a threshold of 50 percent efficacy to consider Covid-19 vaccines for ...